Epidemiological and laboratory studies suggest that nonsteroidal anti-inflammatory drugs
reduce the risk of colon cancer and that the inhibition of colon carcinogenesis is mediated …

Abstract Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers …

A large number of epidemiological studies have shown that regular use of aspirinor other
nonsteroidal anti-inflammatory drugs (NSAIDs) results in a 40–50% reduced risk of …

Colorectal cancer (CRC) is one of the most common neoplasia in Western countries and the
second leading cause of cancer-related death. The vast majority of cases belong to sporadic …

Use of nonsteroidal anti‐inflammatory drugs such as aspirin, which are known to inhibit
cyclooxygenase activity, reduces the relative risk of colorectal cancer in humans by 40–50 …

Colorectal cancer is a major cause of morbidity and mortality accounting for an estimated
550,000 deaths annually worldwide. Colonic neoplasia develops in a stepwise fashion …

Purpose: Nonsteroidal anti-inflammatory drugs reduce the risk of colorectal cancer. The
cyclooxygenase (COX) pathway of arachidonic acid metabolism is an important target for …

Background: Epidemiological studies have revealed a protective effect of NSAIDs, which
principally target cyclooxygenase (COX)-1 and COX-2, on the development of colorectal …

Abstract Background Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed
to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 …

Background Celecoxib has previously been shown to be effective in reducing recurrent
colorectal adenomas, but its long-term effects are unknown. In addition, safety issues are of …